MX2017016114A - Metodos para tratar o prevenir una proteopatia. - Google Patents
Metodos para tratar o prevenir una proteopatia.Info
- Publication number
- MX2017016114A MX2017016114A MX2017016114A MX2017016114A MX2017016114A MX 2017016114 A MX2017016114 A MX 2017016114A MX 2017016114 A MX2017016114 A MX 2017016114A MX 2017016114 A MX2017016114 A MX 2017016114A MX 2017016114 A MX2017016114 A MX 2017016114A
- Authority
- MX
- Mexico
- Prior art keywords
- proteopathy
- methods
- treating
- preventing
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
En la presente se describen métodos para el tratamiento o prevención de una proteopatía.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562174332P | 2015-06-11 | 2015-06-11 | |
US201562174338P | 2015-06-11 | 2015-06-11 | |
PCT/US2016/036945 WO2016201266A1 (en) | 2015-06-11 | 2016-06-10 | Methods of treating or preventing a proteopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017016114A true MX2017016114A (es) | 2018-04-11 |
Family
ID=57503990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017016114A MX2017016114A (es) | 2015-06-11 | 2016-06-10 | Metodos para tratar o prevenir una proteopatia. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20180099974A1 (es) |
EP (1) | EP3307742B1 (es) |
JP (3) | JP6924155B2 (es) |
AU (1) | AU2016274956A1 (es) |
CA (1) | CA2986785A1 (es) |
ES (1) | ES2924433T3 (es) |
HK (1) | HK1252692A1 (es) |
IL (1) | IL256109A (es) |
MX (1) | MX2017016114A (es) |
WO (1) | WO2016201266A1 (es) |
ZA (1) | ZA201708082B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2625534T3 (es) | 2011-04-25 | 2017-07-19 | Usher Iii Initiative | Pirazolopiridazinas y métodos para el tratamiento de enfermedades degenerativas de la retina y pérdida de la audición asociadas con el síndrome de Usher |
US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
US11168082B2 (en) | 2017-05-15 | 2021-11-09 | The Regents Of The University Of Michigan | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors |
CN111171019A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
AU2019385480A1 (en) * | 2018-11-20 | 2021-07-15 | Georgetown University | Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders |
CN113840602A (zh) * | 2019-03-15 | 2021-12-24 | 斯基霍克疗法公司 | 用于校正异常剪接的组合物和方法 |
EP4178580A1 (en) * | 2020-07-09 | 2023-05-17 | Usher III Initiative, Inc. | Treatment of cancer, inflammatory diseases and autoimmune diseases |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011162655A1 (en) * | 2010-06-24 | 2011-12-29 | Alphabeta Ab | Compound and method for treatment of alzheimer's disease and familial dementia |
ES2625534T3 (es) * | 2011-04-25 | 2017-07-19 | Usher Iii Initiative | Pirazolopiridazinas y métodos para el tratamiento de enfermedades degenerativas de la retina y pérdida de la audición asociadas con el síndrome de Usher |
CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
US8765762B2 (en) * | 2012-10-25 | 2014-07-01 | Usher III, Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome |
-
2016
- 2016-06-10 JP JP2017563942A patent/JP6924155B2/ja active Active
- 2016-06-10 ES ES16808401T patent/ES2924433T3/es active Active
- 2016-06-10 MX MX2017016114A patent/MX2017016114A/es unknown
- 2016-06-10 CA CA2986785A patent/CA2986785A1/en active Pending
- 2016-06-10 WO PCT/US2016/036945 patent/WO2016201266A1/en active Application Filing
- 2016-06-10 EP EP16808401.0A patent/EP3307742B1/en active Active
- 2016-06-10 AU AU2016274956A patent/AU2016274956A1/en not_active Abandoned
-
2017
- 2017-11-28 ZA ZA2017/08082A patent/ZA201708082B/en unknown
- 2017-11-29 IL IL256109A patent/IL256109A/en active IP Right Grant
- 2017-12-08 US US15/835,624 patent/US20180099974A1/en not_active Abandoned
-
2018
- 2018-09-18 HK HK18112000.3A patent/HK1252692A1/zh unknown
-
2021
- 2021-07-30 JP JP2021125626A patent/JP2021178849A/ja active Pending
-
2023
- 2023-03-06 JP JP2023033407A patent/JP2023071887A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3307742B1 (en) | 2022-05-18 |
JP6924155B2 (ja) | 2021-08-25 |
ES2924433T3 (es) | 2022-10-06 |
JP2018521026A (ja) | 2018-08-02 |
WO2016201266A1 (en) | 2016-12-15 |
EP3307742A4 (en) | 2019-03-06 |
HK1252692A1 (zh) | 2019-05-31 |
JP2023071887A (ja) | 2023-05-23 |
JP2021178849A (ja) | 2021-11-18 |
IL256109A (en) | 2018-02-28 |
US20180099974A1 (en) | 2018-04-12 |
CA2986785A1 (en) | 2016-12-15 |
ZA201708082B (en) | 2021-03-31 |
EP3307742A1 (en) | 2018-04-18 |
AU2016274956A1 (en) | 2017-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
MA40404A (fr) | Polythérapie pour traiter un paramyxovirus | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
PH12017501999A1 (en) | K-ras modulators | |
IL269371A (en) | Treatment methods | |
GB2541571A (en) | Pharmaceutical compositions | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
EP3362066A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES | |
EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
ZA201700416B (en) | Methods for treating or preventing ophthalmological conditions | |
PH12018502020A1 (en) | Methods for treating and preventing c. difficile infection | |
EA201991818A1 (ru) | Лечение рака | |
MA40457A (fr) | Combinaison de médicaments pour traiter le myélome multiple | |
EP3362065A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES | |
HK1244211A1 (zh) | 治療、預防或降低皮膚感染風險的方法 | |
PH12017501864A1 (en) | Compositions and methods for treating autism | |
IL281792A (en) | Treatment methods | |
PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
ZA201806806B (en) | Method for the treatment or prevention of osteoarthritis. | |
MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
IL262916A (en) | Treatment of side effects resulting from chemo-nervous disorder | |
PT3580211T (pt) | 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de cancro | |
GB201718985D0 (en) | Treatment | |
GB201711677D0 (en) | Combination treatment |